graft-versus-host disease (GvHD)

news

Graft engineering sees potential to reduce GVHD risk in leukemia patients

11 January 2022 | By European Pharmaceutical Review

New study shows risk of developing graft-versus-host disease (GVHD) in leukaemia patients reduced by removing naïve T cells from donor blood used for stem cell grafts.

news

First drug for acute graft-versus-host disease prevention approved by FDA

22 December 2021 | By Hannah Balfour (European Pharmaceutical Review)

BMS’s Orencia (abatacept) has been approved by the US FDA for prophylaxis of acute graft-versus-host disease (aGvHD) in patients aged two years plus.

news

Combining pacritinib with sirolimus-based GvHD prophylaxis may improve efficacy

24 March 2021 | By Hannah Balfour (European Pharmaceutical Review)

Phase I results suggest adding pacritinib to sirolimus and low-dose tacrolimus could be beneficial in preventing graft-versus-host disease (GvHD).

news

Microbiome biotherapeutic shows promise in acute graft-versus-host disease

19 March 2021 | By Hannah Balfour (European Pharmaceutical Review)

MaaT013 was safe and generated complete or very good partial responses in a third of patients with steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease.

article

A crucial turning point for increasing patient access to ATMPs

26 October 2020 | By Dr Jane Hollywood (CMS), Dr Robert Stephen (CMS)

Numerous developments are ongoing to make advanced therapy medicinal products (ATMPs) more accessible, effective and less expensive. Here, legal experts Robert Stephen and Jane Hollywood from CMS discuss the increasing prevalence of these highly regulated therapies and the challenges faced by innovators in this space.

news

Abatacept improves survival in patients with acute GvHD

11 December 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

A drug used to treat rheumatoid arthritis improves survival after hematopoietic stem cell transplant...